Infectious Diseases (except HIV/AIDS)
Showing page 164 of 716 pages of list content
-
Durability of the immune response to a third BNT162b2 dose; five months follow-up
This article's authors -
UB-612, a Multitope Universal Vaccine Eliciting a Balanced B and T Cell Immunity against SARS-CoV-2 Variants of Concern
This article's authors -
EBV deletions as biomarkers of response to treatment of Chronic Active Epstein Barr Virus
This article's authors -
Accident and emergency (AE) attendance in England following infection with SARS-CoV-2 Omicron or Delta
This article's authors -
SARS-CoV-2 outbreaks in secondary school settings in the Netherlands during fall 2020; silent circulation
This article's authors -
An Early Return-to-Work Program for COVID-19 Close Contacts in Healthcare During the Omicron Wave in Japan
This article's authors -
Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru
This article's authors -
Describing COVID-19 Patients During The First Two Months of Paxlovid (Nirmatrelvir/Ritonavir) Initiation in a Large HMO in Israel
This article's authors -
Immunogenicity and safety of the CoronaVac inactivated SARS-CoV-2 vaccine in people with underlying medical conditions: a retrospective study
This article's authors -
Outcomes of convalescent plasma with defined high- versus lower-neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus Inactivating Plasma (CoVIP), double-blind phase 2 study
This article's authors